Acquired thrombophilia

Journal of Pharmacy Practice

Volumn 27, Issue 3, 2014, Pages 234-242

  Armstrong, Emily M ^a,b   Bellone, Jessica M ^c   Hornsby, Lori B ^a,d   Treadway, Sarah ^a,b   Phillippe, Haley M ^a,e  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c Department of Pharmaceutical Sciences   (United States)

^d Midtown Medical Center   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired thrombophilia; Antiphospholipid antibodies; Human immunodeficiency virus; Malignancy; Oral contraceptives; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; ARGATROBAN; BEVACIZUMAB; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; FONDAPARINUX; GESTAGEN; HEPARIN; HIRULOG; HYDROXYCHLOROQUINE; INDINAVIR; LENALIDOMIDE; LEVONORGESTREL; LOW MOLECULAR WEIGHT HEPARIN; MEGESTROL ACETATE; NELFINAVIR; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG; WARFARIN; HOST FACTOR;

ACQUIRED THROMBOPHILIA; AIDS RELATED COMPLEX; ANOREXIA; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CD4 LYMPHOCYTE COUNT; CENTRAL VENOUS CATHETER; DRUG MEGADOSE; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; INTRAVENOUS DRUG ABUSE; LOW DRUG DOSE; MORTALITY; OPPORTUNISTIC INFECTION; ORAL CONTRACEPTION; PRACTICE GUIDELINE; RISK FACTOR; SURGICAL PATIENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; DISEASE ASSOCIATION; HUMAN IMMUNODEFICIENCY VIRUS; NEOPLASM; NONHUMAN; ORAL CONTRACEPTIVE USE; RISK ASSESSMENT; COMPLICATION;

ANTIPHOSPHOLIPID SYNDROME; HIV INFECTIONS; HUMANS; NEOPLASMS; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84904746575     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014530424     Document Type: Article

References (86)

1. Centers for Disease Control and Prevention. Venous thromboembolism in adult hospitalizations-United States, 2007-2009. MMWR Morb Mortal Wkly Rep. 2012; 61(22): 401-404.
2. Mahan CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: Annualized United States models for total, hospital-Acquired and preventable costs utilizing long-term attack rates. Thromb Haemost. 2012; 108(2): 291-302.
3. Gezer S. Antiphospholipid syndrome. Dis Mon. 2003; 49(12): 696-741.
4. Sammaritano L. Antiphospholipid syndrome: review. South Med J. 2005; 98(6): 617-625.
5. Hanly J. Antiphospholipid syndrome: an overview. CMAJ. 2003; 168(13): 1675-1682. (Pubitemid 36801931)
6. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification of criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006; 4(2): 295-306.
7. Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta. 2005; 357(1): 17-33. (Pubitemid 40823052)
8. Tincani A, Bazzani C, Zinarelli S, et al. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost. 2008; 34(3): 267-273.
9. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46(4): 1019-1027. (Pubitemid 34303815)
10. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101(5): 1827-1832. (Pubitemid 36237580)
11. Muscal E, Brey R. Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence based medicine. Int J Clin Pract. 2007; 61(9): 1561-1568. (Pubitemid 47228611)
12. Ruiz-Irastorza, Cuadrado MJ, Ruiz-Arruza, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid-Antibody-positive patients: Report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus. 2011; 20(2): 206-218.
13. Brey RL, Hart RG, Sherman DG, et al. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 1990; 40(8): 1190-1196. (Pubitemid 20244973)
14. Kiser KL, Badowski ME. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy. 2010; 30(12): 1292-1302.
15. Bibas M, Biava G, Antinori A. HIV-Associated venous thromboembolism. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011030. doi: 10. 4084/MJHID. 2011. 030.
16. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Haemost. 2002; 28(6): 555-567. (Pubitemid 36026999)
17. Copur AS, Smith PR, Gomez C, et al. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS. 2002; 16(5): 205-209. (Pubitemid 34478160)
18. Callen S, Florence E, Philippe M, et al. Mixed arterial and venous thromboembolism in a person with HIV infection. Scand J Infect Dis. 2003; 35(11-12): 907-908. (Pubitemid 38028942)
19. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001; 86(1): 452-463. (Pubitemid 32663974)
20. Jacobsen MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis. 2004; 39(8): 1214-1222. (Pubitemid 40169322)
21. Lijfering WM, Ten Kate MK, Sprenger HG, et al. Absolute risks of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost. 2006; 4(9): 1928-1930. (Pubitemid 44226770)
22. Sullivan PS, Dworkin MS, Jones JL, et al. Epidemiology of thrombosis in HIV-infected individuals: the adult/adolescent spectrum of HIV disease project. AIDS. 2000; 14(3): 321-324. (Pubitemid 30132927)
23. Stahl CP, Wideman CS, Spira TJ, et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood. 1993; 81(7): 1801-1807. (Pubitemid 23101593)
24. Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS. 2001; 15(1): 15-24. (Pubitemid 32104583)
25. Bissuel F, Berruyer M, Causse X, et al. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr. 1992; 5(5): 484-489.
26. Sorice M, Griggi T, Arcieri P, et al. Protein S and HIV infection: the role of anticardiolipin and anti-protein S antibodies. Thromb Res. 1994; 73(3-4): 165-175.
27. Feffer SE, Fox RL, Orsen MM, et al. Thrombotic tendencies and correlation with clinical status inpatients infected with HIV. South Med J. 1995; 88(11): 1126-1130.
28. Levine AM, Vigen C, Gravink J, et al. Progressive prothrombotic state in women with advancing HIV disease. J Acquir Immune Defic Syndr. 2006; 42(5): 572-577. (Pubitemid 44162425)
29. Erbe M, Rickerts V, Bauersachs RM, et al. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost. 2003; 9(4): 325-331. (Pubitemid 37414123)
30. Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R, et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost. 2004; 10(1): 19-25. (Pubitemid 38543713)
31. Syed FF, Beeching NJ. Lower-limb deep-vein thrombosis in a general hospital: risk factors, outcome and the contribution of intravenous drug use. QJM. 2005; 98(2): 139-145. (Pubitemid 40277570)
32. Rasmussen LD, Dybdal M, Gerstoft J, et al. HIV and risk of venous thromboembolism: a Danish nationwide populationbased cohort study. HIV Med. 2011; 12(4): 202-210.
33. Crum-Cianflone NF, Weekes J, Bavaro M. Review: thrombosis among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS. 2008; 22(10): 771-778.
34. Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV infected adults and adolescents. MMWR Recomm Rep. 2009; 58(RR-4): 1-207.
35. Jenkins RE, Peters BS, Pinching AJ. Thromboembolic disease in AIDS is associated with cytomegalovirus disease. AIDS. 1991; 5(12): 1540-1542.
36. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. NEngl JMed. 1995; 332(20): 1330-1335.
37. Linkins LA, Dans AL,Moores KL, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th edition: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl): e495S-e530S.
38. Anderson JAM, Weitz JI. Hypercoagulable states. Clin Chest Med. 2010; 31(4): 659-673.
39. Warkentin TE, Sheppard JI. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev. 2006; 20(4): 259-272. (Pubitemid 44428106)
40. Francis JL, Palmer GP III, Moroose R, et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg. 2003; 75(1): 17-22. (Pubitemid 36099015)
41. Lindhoff-Last E, Nakov R, Misselwitz F, et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated heparin or lowmolecular-weight heparin. Br J Haematol. 2002; 118(4): 1137-1142. (Pubitemid 35025982)
42. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a populationbased case-control study. Arch Intern Med. 2000; 160(6): 809-815. (Pubitemid 30165241)
43. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293(6): 715-722. (Pubitemid 40216041)
44. Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol. 2001; 73(2): 137-144. (Pubitemid 33758852)
45. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol. 2001; 106(1-2): 25-32. (Pubitemid 32830513)
46. Ruf W. Molecular regulation of blood clotting in tumor biology. Haemostasis. 2001; 31(suppl 1): 5-7.
47. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med. 1993; 119(8): 819-827. (Pubitemid 24012648)
48. Kyrle P, Eichinger S. Deep vein thrombosis. Lancet. 2005; 365(9465): 1163-1174. (Pubitemid 40417567)
49. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients. antithrombotic therapy and prevention of thrombosis, 9th edition: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141: e195S-e226S.
50. Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J. 2002; 23(12): 984-990. (Pubitemid 35203878)
51. Bloemenkamp KW, Rosendaal FR, Buller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999; 159(1): 65-70. (Pubitemid 29044121)
52. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001; 344(20): 1527-1535. (Pubitemid 32429213)
53. Lidegaard O, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national followup study. BMJ. 2009; 339: b2890.
54. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestin components. Lancet. 1995; 346(8990): 1589-1593. (Pubitemid 26001840)
55. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drosperinone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007; 75(5): 344-354. (Pubitemid 46551071)
56. Seeger JD, Loughlin J, Eng MP, et al. Risk of thromboembolism in women taking ethinylestradiol/drosperinone and other oral contraceptives. Obstet Gynecol. 2007; 110(3): 587-593. (Pubitemid 47359582)
57. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. FDA 2011. CHC-CVD final repot 111022v2. Accessed from: www. fda. gov/downloads/Drugs/Drug Safety/UCM277384. pdf. Accessed: June 1, 2012.
58. Holbrook A, Schulman S, Witt DM. Evidence based management of anticoagulant therapy. antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl): e152s-e84s.
59. The APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004; 291(5): 576-584.
60. Ruiz-Irastorza G, Hunt B, Khmashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007; 57(8): 1487-1495. (Pubitemid 350308848)
61. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992; 117(4): 303-308.
62. Khmashta MA, Cudardo MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med. 1995; 332(15): 993-997.
63. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005; 3(5): 848-853. (Pubitemid 41632808)
64. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med. 2003; 349(12): 1133-1138. (Pubitemid 37122325)
65. Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood. 2009; 114(10): 2020-2030.
66. Okuma H, Kitagawa Y, Takashi Y, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2010; 7(1): 15-18.
67. Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, et al. Efficacy and safety of long term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis. 2011; 70(9): 1652-1654.
68. Dentali F, Manfredi E, Crowther M, et al. Long duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005; 3(9): 2121-2123. (Pubitemid 43086081)
69. Scoble T, Wijetilleka S, Khamasthta MA. Management of refractory anti-phospholipid syndrome. Autoimmun Rev. 2011; 10(11): 669-773.
70. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010; 376(9751): 1498-1509.
71. Jajoria P,Murthy V, Papalardo E, et al. Statins for the treatment of antiphospholipid syndrome. Ann N Y Acad Sci. 2009; 1173: 736-745.
72. Lopez-Pedrera C, Ruiz-Limon, Aquirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome [abstract]. Ann Rheum Dis. 2011; 70(4): 675-682.
73. Rivaroxaban in Antiphospholipid Syndrome (APS). In: Controlled-Trials. com [Internet]. Available from: Current Controlled Trials. [Accessed: January 8, 2014]. Identifier: ISRCTN6822280.
74. Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Tromb Haemost. 2011; 9(12): 2389-2396.
75. Kuo KH, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost. 2005; 93(5): 999-1000. (Pubitemid 40691563)
76. Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008; 99(1): 208-2014.
77. Grouzi E, Kyriakou E, Panagou I, et al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a singlecenter experience. Clin Appl Thromb Hemost. 2010; 16(6): 663-667.
78. Pappalardo F, Scandroglio A, Maj G, et al. Treatment of heparininduced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux. J Thorac Cardiovasc Surg. 2010; 139(3): 790-792.
79. Dager WR, White RH. Treatment of Heparin-Induced Thrombocytopenia. Ann Pharmacother. 2002; 36(3): 489-503. (Pubitemid 34205325)
80. Lee AY, Levine MN, Baker RI, et al. Randomized, comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent, venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146-153.
81. Guyatt G, Norris S, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl): 53s-70s.
82. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl): e619s-e726s.
83. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology practice guideline update. J Clin Oncol 2013; 31(17): 2189-2204.
84. StreiffMB,Bockenstedt PL,Cataland SR, et al. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013; 11(11): 1402-1429.
85. Khorana AA, Spyropoulos AC, Zwicker J, et al. Preventing VTE in outpatients with cancer. Chest. 2012; 142(1): 265-266.
86. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depotmedroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010; 30(11): 2297-2300.